Thomas P Power
Overview
Explore the profile of Thomas P Power including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen C, Crowe C, Kuti E, Donato B, Djaraher R, Seman L, et al.
J Health Econ Outcomes Res
. 2024 May;
11(1):112-121.
PMID: 38779335
The economic burden associated with type 2 diabetes mellitus (T2DM) and concurrent cardiovascular disease (CVD) among patients with COVID-19 is unclear. We compared healthcare resource utilization (HCRU) and costs in...
2.
Nguyen C, Bamber L, Willey V, Evers T, Power T, Stephenson J
Patient Prefer Adherence
. 2023 May;
17:1181-1196.
PMID: 37163154
Background: Patient-reported health related quality of life (HRQOL) is not routinely assessed in clinical practice. Little is known about health status outcomes reported by patients with heart failure with preserved...
3.
Nguyen C, Crowe C, Kuti E, Narsipur N, Donato B, Pepe R, et al.
Diabetes Obes Metab
. 2023 Mar;
25(9):2464-2472.
PMID: 36999236
Aim: To compare adverse outcomes among COVID-19 patients with pre-existing type 2 diabetes (T2D) only, T2D and cardiovascular disease (CVD), or neither. Methods: This retrospective cohort study used administrative claims,...
4.
Nguyen C, Zhang X, Evers T, Willey V, Tan H, Power T
Am Health Drug Benefits
. 2020 Dec;
13(4):166-174.
PMID: 33343816
Background: Although the significant burden of heart failure (HF) is well recognized, the relative contributions of systolic HF versus diastolic HF are less defined. Objective: To explore the differential burden...
5.
Power T, Ke X, Zhao Z, Bonine N, Cziraky M, Grabner M, et al.
Vasc Health Risk Manag
. 2018 Feb;
14:23-36.
PMID: 29440909
Purpose: The aim of this study was to investigate real-world patient characteristics, medication use, and health care resource utilization (HCRU) and costs among patients with clinical atherosclerotic cardiovascular disease (ASCVD)...
6.
Huang Q, Grabner M, Sanchez R, Willey V, Cziraky M, Palli S, et al.
Am Health Drug Benefits
. 2017 May;
9(8):434-444.
PMID: 28465771
Background: The American College of Cardiology (ACC)/American Heart Association (AHA) 2013 guidelines for blood cholesterol treatment recommend high-intensity statins for adults with atherosclerotic cardiovascular disease (ASCVD). Currently, little is known...
7.
Cziraky M, Reddy V, Luthra R, Xu Y, Wilhelm K, Power T, et al.
J Manag Care Spec Pharm
. 2015 May;
21(6):470-7.
PMID: 26011548
Background: The presence of type 2 diabetes mellitus magnifies the risks associated with acute coronary syndrome (ACS), increasing the risk of recurrent cardiovascular events (CVEs) and doubling the risk of...
8.